relapsed/refractory
Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non Hodgkin lymphoma
... with relapsed or refractory non-Hodgkin lymphoma (NHL) ...(i.e., relapsed vs. refractory), patient physical condition, and disease-spe- cific prognostic and other risk ...in ...
9
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
... of relapsed/refractory MZL based on pivotal open-label Phase II trial demonstrated an overall response rate of 48%, with a complete response rate of 3%, median progression-free survival of ...
10
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
... with relapsed/refractory PTCL had more frequent hematologic toxicities and grade ≥ 3 ...with relapsed/refractory PTCL and 36% of patients with relapsed/refractory CTCL continued ...
10
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
... and relapsed/refractory NK/T-cell lymphoma should be treated with L- asparaginase-containing regimens that incorporate non- MDR-dependent drugs [17, ...with relapsed/refractory NKTCL are ...
8
Temozolomide and cisplatin in relapsed/refractory acute leukemia
... are summarized in Table 2. Fifteen patients had AML, of whom 5 patients had MDS that evolved to AML and one had aplastic anemia that evolved to AML. Five of the patients with AML had primary refractory disease. ...
6
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
... in relapsed/refractory AML, ALL, CLL, SLL, PLL, and T-cell lymphomas and as maintenance therapy in myeloma as well as a dose-finding study of higher doses of carfilzomib are currently ...
20
Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
... Food and Drug Administration for myeloma patients who have received at least two prior therapies, including bortezomib and an immunomodulatory therapy. Further studies that are underway will provide insight for further ...
11
Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
... Relapsed PTCL has historically carried a very poor prog- nosis, with few therapeutic options. To date, belinostat monotherapy has been evaluated in relapsed/refractory PTCL with promising results. ...
7
<p>Carfilzomib for relapsed and refractory multiple myeloma</p>
... develop relapsed refractory ...of relapsed and/or refractory MM, as a single agent with or without dexamethasone, and in combination with lenalidomide in 2012 and 2015, ...
13
Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
... with relapsed or refractory HL [12, 13], has been approved in the United States and Europe for the treatment of HL after failure of AHSCT or after failure of two or more previous multia- gent chemotherapy ...
10
Ockham’s razor for the MET driven invasive growth linking idiopathic pulmonary fibrosis and cancer
... Relapsed/refractory multiple myeloma; locally advancer or [73–90]a metastatic colorectal cancers; metastatic triple negative breast cancers; childhood relapsed/refractory solid tumors; r[r] ...
12
Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
... Administration has changed the indication for duration of drug administration due to positive results from this trial and the package insert for BV no longer contains the 16-cycle limit. Studies are ongoing to examine ...
7
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
... with relapsed or refractory ...of relapsed or refractory HL, though some side effects still occurred in patients, accord- ing to clinical ...with relapsed/refractory CD30 ...
5
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
... enrolled into four pomalidomide dose-level cohorts: 2 mg (n = 6); 3 mg (n = 8); 4 mg (n = 14); and 5 mg (n = 10). Patients had received a median of six prior anti-myeloma treatments (range, 2–17). Sixty-three percent of ...
8
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
... Notes: Proteasomes are intracellular structures which catabolize proteins that are marked with ubiquitin. Pi block this mechanism of action causing accumulation of proteins triggering cell death. New molecular target ...
16
Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
... Abstract: Carfilzomib is a second-generation proteasome inhibitor with well-documented clinical activity as a single agent in patients with relapsed/refractory multiple myeloma. Carfilzomib can partially ...
8
Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi
... dacinostat, and panobinostat, inhibit proliferation and lead to apoptosis of multiple myeloma cells and murine xenograft models. However, in phase I and phase II clinical trials, is has been observed that as a single ...
15
Original Article A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide
... logic malignancies. Approximately 86,000 new cases of MM were reported annually worldwide [1]. Lenalidomide is an oral immunomodulatory drug (IMiD) approved in the United States for patients with MM. The introduction of ...
5
Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom
... Results: In total, 123 participants were recruited and included in the final analysis; all participants gave written, informed consent. Complete remission was the most preferred health state (mean utility [SEM], 0.86 ...
7
<p>Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date</p>
... Of particular interest is tocilizumab, a humanized, immunoglobin G1κ (IgG1κ) anti-human interleukin-6 receptor (anti-IL-6R) monoclonal antibody (mAb) that originally received US Food and Drug Administration (FDA) ...
10